Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03907046 · ClinicalTrials.gov registry record · Phase 3
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
A Phase 3 study of Atrial Fibrillation and Intracerebral Hemorrhage, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT03907046: Recruiting Phase 3 study of Atrial Fibrillation and Intracerebral Hemorrhage, sponsored by Yale University.
NCT03907046 is a Phase 3 study of Atrial Fibrillation and Intracerebral Hemorrhage that is actively recruiting participants, run by Yale University. The registered enrollment target is 700 participants, below the 2,993-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03907046, a Phase 3 study of Atrial Fibrillation and Intracerebral Hemorrhage, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Primary Outcome
Incidence of stroke of any type (ischemic or hemorrhagic) or death from any cause
Conditions Studied
Interventions
- DRUG Aspirin
- DRUG Apixaban
Study Locations (20)
California
- Mercy San Juan Medical Center - Carmichael
- Eden Medical Center, Castro Valley - Castro Valley
- Arrowhead Regional Medical Center - Colton
- Rancho Los Amigos National Rehabilitation Center - Downey
- Kaiser Permanente Fontana Medical Center - Fontana
- Community Regional Medical Center of Fresno - Fresno
- St. Jude Medical Center - Fullerton
- Long Beach Memorial Medical Center - Long Beach
- Los Alamitos Medical Center - Los Alamitos
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Ronald Reagan UCLA Medical Center - Los Angeles
- Doctors Medical Center Modesto, Modesto, CA - Modesto
- Hoag Hospital Newport Beach - Newport Beach
Arizona
- Chandler Regional Medical Center - Chandler
- St. Joseph's Hospital and Medical Center - Phoenix
- Banner University Medical Center - Tucson
Alabama
- University of Alabama Hospital - Birmingham
- University of South Alabama University Hospital - Mobile
Arkansas
- UAMS Medical Center - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2020-01-28 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
What NCT03907046 shows while recruiting
NCT03907046 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, below the 2,993-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Aspirin is the first listed.
NCT03907046 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT03907046 about?
NCT03907046 is a clinical study titled "Anticoagulation in ICH Survivors for Stroke Prevention and Recovery". Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in b...
What is the current status of trial NCT03907046?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2020-01-28. Estimated completion is 2027-04.
What conditions does trial NCT03907046 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Intracerebral Hemorrhage.
What interventions are being tested in trial NCT03907046?
The interventions under investigation include: Aspirin (DRUG), Apixaban (DRUG).
Who is sponsoring clinical trial NCT03907046?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03907046 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03907046's enrollment target sits among peer trials
700 43rd of 202 higher than 160 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI